MediciNova receives notice of allowance for new patent covering MN-001 and MN-002
MediciNova, Inc., and the JASDAQ Market of the Tokyo Stock Exchange announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for a pending patent application which covers MN-001 (tipelukast) and MN-002 (a major metabolite of MN-001) for the treatment of hypertriglyceridemia, hypercholesterolemia, and hyperlipoproteinemia.
[adsense:336x280:8701650588]
Once issued, the patent maturing from this allowed patent application is expected to expire no earlier than July 2034.
[adsense:468x15:2204050025]
The allowed claims cover a method of reducing a triglyceride blood level, a method of reducing a total cholesterol blood level, and a method of reducing a low density lipoprotein (LDL) blood level using MN-001 or MN-002. The allowed claims cover oral administration including liquid and solid dosage forms.